Bott Oliver J, Hoffmann Ina, Bergmann Joachim, Gusew Nathalie, Schnell Oliver, Gómez Enrique J, Hernando M Elena, Kosche Patrick, von Ahn Christian, Mattfeld Dirk C, Pretschner Dietrich P
Institute for Medical Informatics, Technical University of Braunschweig, Muehlenpfordtstr. 23, D-38106 Braunschweig, Germany.
Int J Med Inform. 2007 Dec;76 Suppl 3:S447-55. doi: 10.1016/j.ijmedinf.2007.06.002. Epub 2007 Jul 25.
INCA (Intelligent Control Assistant for Diabetes) is an EU funded project aimed at improving diabetes therapy by creating a personal closed-loop system interacting with telemedical remote control. This study aims at identifying and applying suitable methods for a cost-benefit analysis from the perspective of the payor for health services.
For cost analysis MOSAIK-M was used, a method and tool for health information systems analysis and design. Two MOSAIK-M models were created describing conventional insulin pump based diabetes care (CSII), and INCA based diabetes care. Both models were parameterized with costs and simulated to determine yearly costs of diabetes management and treatment for a patient with no diabetes related complications. Probability of developing complications and their duration were determined based on the Archimedes model. It was parameterized with results of a clinical study concerning HbA1c-value changes using the INCA system compared with conventional CSII. The simulation results in form of years of disease within a 30-year time frame were multiplied with corresponding treatment costs.
Yearly costs of conventional insulin CSII for a diabetes type 1 patient are euro 5908 (German health care system). Using INCA based on the clinical study setting would raise yearly costs by euro 2233. 24% of the INCA costs are generated by the continuous blood glucose measurement device, 5% by IT devices and services. Considering also diabetes related complications in a 30-year time frame and HbA1c value reductions from 7.9 and 7.6% (conventional CSII) to 7.5 and 7.3% (INCA) reduces the additional costs of INCA to euro 2102 and euro 2162.
The approach produces an estimation of a lower bound for cost savings concerning the treatment of diabetes related complications in a 30-year time frame. These savings alone do not prove cost efficiency of the INCA approach. Further work is needed to improve the approximation and to include indirect and intangible costs.
INCA(糖尿病智能控制助手)是一个由欧盟资助的项目,旨在通过创建一个与远程医疗遥控交互的个人闭环系统来改善糖尿病治疗。本研究旨在从卫生服务支付方的角度识别并应用合适的成本效益分析方法。
成本分析使用了MOSAIK-M,这是一种用于卫生信息系统分析与设计的方法和工具。创建了两个MOSAIK-M模型,分别描述基于传统胰岛素泵的糖尿病护理(CSII)和基于INCA的糖尿病护理。两个模型都用成本进行了参数化,并进行模拟以确定一名无糖尿病相关并发症患者的糖尿病管理和治疗的年度成本。并发症发生的概率及其持续时间是根据阿基米德模型确定的。该模型用一项关于使用INCA系统与传统CSII相比的糖化血红蛋白(HbA1c)值变化的临床研究结果进行了参数化。在30年时间框架内以疾病年数形式呈现的模拟结果与相应的治疗成本相乘。
一名1型糖尿病患者使用传统胰岛素CSII的年度成本为5908欧元(德国医疗保健系统)。根据临床研究设定使用INCA会使年度成本增加2233欧元。INCA成本的24%由连续血糖测量设备产生,5%由信息技术设备和服务产生。考虑到30年时间框架内的糖尿病相关并发症以及糖化血红蛋白值从7.9%和7.6%(传统CSII)降至7.5%和7.3%(INCA),INCA的额外成本降至2102欧元和2162欧元。
该方法得出了在30年时间框架内糖尿病相关并发症治疗成本节约下限的估计值。仅这些节约并不能证明INCA方法具有成本效益。需要进一步开展工作以改进近似值并纳入间接和无形的成本。